Study guide

13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics

Key Takeaways Explain This Topic AI

Km is the substrate concentration at half of Vmax (lower Km means higher affinity); competitive inhibitors raise apparent Km with unchanged Vmax, and noncompetitive inhibitors lower Vmax with unchanged Km.

Southern blots detect DNA, Northern blots RNA and Western blots protein; PCR amplifies DNA, RT-PCR detects RNA (as in SARS-CoV-2 testing), and FISH localizes sequences on chromosomes.

Nucleotide excision repair (thymine dimers) fails in xeroderma pigmentosum; mismatch repair fails in Lynch syndrome; homologous recombination fails with BRCA1 or BRCA2 mutations.

RNA polymerase II makes mRNA and is inhibited by alpha-amanitin; the pre-mRNA is capped, polyadenylated and spliced, and anti-Smith antibodies target the spliceosome in SLE.

Tay-Sachs (hexosaminidase A) has a cherry-red spot without organomegaly; Niemann-Pick (sphingomyelinase) has a cherry-red spot with hepatosplenomegaly; Gaucher (glucocerebrosidase), the most common, has crumpled-tissue-paper macrophages.

Last updated: October 2026

Why this area matters

The TOS lists:

"gene expression (molecular basis of oncogenesis, techniques in molecular biology research, molecular and genetic-based therapeutic methods)";

"enzymes: properties and function, substrate binding, kinetics, regulation, inhibition".

Molecular diagnostics such as GeneXpert for tuberculosis, RT-PCR for COVID-19, newborn screening and HbA1c are now routine in Philippine practice, so the principles behind them are tested.

Eukaryotic DNA Replication Machinery and Telomere Maintenance

DNA replication in human cells is semiconservative, bidirectional, and occurs during the S-phase of the cell cycle at multiple origins of replication (AT-rich consensus sequences).

Enzymatic Orchestration at the Replication Fork

DNA Helicase: Unwinds the double helix at the replication fork by breaking hydrogen bonds between base pairs. Mutations in the BLM (RecQ helicase) gene cause Bloom Syndrome (dwarfism, telangiectatic erythema, chromosomal instability, and cancer predisposition).

Single-Stranded DNA-Binding Proteins (RPA in eukaryotes): Bind exposed single strands to prevent reannealing and hairpins.

Topoisomerases (Type I and II): Create transient single-strand (Type I) or double-strand (Type II) nicks to relieve negative and positive torsional supercoiling ahead of the advancing replication fork.

Pharmacological Targets: Fluoroquinolones (ciprofloxacin) inhibit prokaryotic topoisomerase II (DNA gyrase) and topoisomerase IV. Etoposide/teniposide inhibit eukaryotic Topoisomerase II. Irinotecan/topotecan inhibit eukaryotic Topoisomerase I.

Primase: Specialized RNA polymerase that synthesizes short ( 10 bp 10\text{ bp} 10 bp ) RNA primers required to provide free 3 ′ -OH 3'\text{-OH} 3 ′ -OH groups for DNA polymerases.

Eukaryotic DNA Polymerases:

DNA Polymerase α \alpha α : Associates with primase to initiate synthesis by adding a short run of DNA onto the RNA primer.

DNA Polymerase δ \delta δ : Synthesizes the lagging strand (Okazaki fragments); possesses 3 ′ → 5 ′ 3'\to 5' 3 ′ → 5 ′ exonuclease proofreading activity.

DNA Polymerase ϵ \epsilon ϵ : Synthesizes the continuous leading strand in the 5 ′ → 3 ′ 5'\to 3' 5 ′ → 3 ′ direction; possesses 3 ′ → 5 ′ 3'\to 5' 3 ′ → 5 ′ exonuclease proofreading activity.

DNA Polymerase β \beta β : Exclusively involved in Base Excision Repair (BER).

DNA Polymerase γ \gamma γ : Replicates and repairs mitochondrial DNA.

DNA Ligase: Catalyzes the formation of phosphodiester bonds to seal Okazaki fragment nicks, consuming ATP.

Telomerase Dynamics in Aging and Oncogenesis

Because DNA polymerases require an RNA primer and synthesize strictly 5 ′ → 3 ′ 5'\to 3' 5 ′ → 3 ′ , the removal of the terminal lagging-strand primer leaves an unreplicated 3 ′ 3' 3 ′ gap (the "end-replication problem"). Telomerase is a specialized ribonucleoprotein complex acting as an RNA-dependent DNA polymerase (reverse transcriptase) . It carries an internal RNA template ( 3 ′ -CAAUCCCAAUC- 5 ′ 3'\text{-CAAUCCCAAUC-}5' 3 ′ -CAAUCCCAAUC- 5 ′ ) that directs the addition of tandem non-coding hexanucleotide repeats ( 5 ′ -TTAGGG- 3 ′ 5'\text{-TTAGGG-}3' 5 ′ -TTAGGG- 3 ′ ) onto the 3 ′ 3' 3 ′ ends of eukaryotic chromosomes.

Active in germ cells, hematopoietic stem cells, and basal skin keratinocytes; inactive in differentiated somatic cells, leading to progressive telomere shortening that triggers replicative senescence (the Hayflick limit).

Reactivated in > 85 − 90 % >85-90\% > 85 − 90% of human malignancies , enabling limitless replicative immortality.

DNA Repair Mechanisms and Human Genomic Instability Syndromes

Repair Pathway Type of DNA Lesion Repaired Cell Cycle Phase Key Enzymatic Mediators Associated Clinical Syndrome

Nucleotide Excision Repair (NER) Bulky, helix-distorting lesions; UV-induced pyrimidine (thymine-thymine) dimers G1 Phase Endonucleases (excision), DNA Pol δ / ϵ \delta/\epsilon δ / ϵ , DNA Ligase Xeroderma Pigmentosum (autosomal recessive; severe photosensitivity, poikiloderma, > 1000 -fold >1000\text{-fold} > 1000 -fold increased risk of melanoma and squamous cell carcinomas)

Base Excision Repair (BER) Non-bulky base damage (spontaneous deamination of cytosine to uracil; alkylation; oxidation) Throughout Cell Cycle DNA Glycosylase (removes base creating AP site), AP-Endonuclease (cleaves 5 ′ 5' 5 ′ end), AP-Lyase (cleaves 3 ′ 3' 3 ′ end), DNA Pol β \beta β , Ligase Normal cellular aging; base maintenance ( Mnemonic: " GEL P lease" = Glycosylase, Endonuclease, Lyase, Polymerase)

Mismatch Repair (MMR) Base-base mismatches and small insertion/deletion loops escaped from replication proofreading S / G2 Phase M S H 2 , M L H 1 , M S H 6 , P M S 2 MSH2, MLH1, MSH6, PMS2 MS H 2 , M L H 1 , MS H 6 , PMS 2 proteins; recognizes unmethylated daughter strand Lynch Syndrome (HNPCC) (autosomal dominant; microsatellite instability; high risk of colorectal, endometrial, and ovarian cancers)

Non-Homologous End Joining (NHEJ) Double-strand DNA breaks Any Phase (G0/G1) Ku70/Ku80 heterodimer, DNA-PKcs, Artemis endonuclease, DNA Ligase IV Ataxia-Telangiectasia ( ATM gene defect; cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, ionizing radiation sensitivity)

Homologous Recombination (HR) Double-strand DNA breaks Late S / G2 Phase (requires sister chromatid template) B R C A 1 , B R C A 2 , R A D 51 BRCA1, BRCA2, RAD51 BRC A 1 , BRC A 2 , R A D 51 ; error-free repair Familial Breast and Ovarian Cancer Syndromes (autosomal dominant BRCA1/BRCA2 mutations; hypersensitivity to PARP inhibitors)

Eukaryotic Transcription and Post-Transcriptional Processing

Eukaryotic transcription is catalyzed by three distinct RNA polymerases, each dedicated to specific RNA subclasses:

RNA Polymerase I: Synthesizes large ribosomal RNAs ( 28S, 18S, and 5.8S rRNA ) in the nucleolus.

RNA Polymerase II: Synthesizes messenger RNA (pre-mRNA) , small nuclear RNAs (snRNAs), and microRNAs.

Toxicity: Ingestion of the Death Cap mushroom ( Amanita phalloides ) causes ingestion of α \alpha α -amanitin , a cyclic octapeptide that binds tightly to RNA Polymerase II, halting mRNA synthesis and triggering massive hepatic centrilobular necrosis and renal tubular failure.

RNA Polymerase III: Synthesizes tRNA and 5S rRNA .

Mnemonic: "RNA Pol I, II, III = R ampant, M assive, T iny" ( r RNA, m RNA, t RNA).

Eukaryotic Promoters and Pre-mRNA Processing

Transcription initiation requires the recognition of promoter consensus sequences: the TATA box (Hogness box, located − 25 to − 30 bp -25\text{ to }-30\text{ bp} − 25 to − 30 bp upstream) and the CAAT box ( − 75 to − 80 bp -75\text{ to }-80\text{ bp} − 75 to − 80 bp upstream). Enhancers (binding activators) and Silencers (binding repressors) can reside upstream, downstream, or within introns, looping DNA to modulate transcription rates.

Nascent pre-mRNA undergoes three obligatory processing events inside the nucleus prior to nuclear export:

5 ′ 5' 5 ′ Capping: Addition of 7-methylguanosine via an unusual 5 ′ -to- 5 ′ 5'\text{-to-}5' 5 ′ -to- 5 ′ triphosphate bridge; protects against exonuclease degradation and serves as the ribosomal binding signal for translation initiation.

3 ′ 3' 3 ′ Polyadenylation: Cleavage at the downstream consensus sequence ( 5 ′ -AAUAAA- 3 ′ 5'\text{-AAUAAA-}3' 5 ′ -AAUAAA- 3 ′ ), followed by the template-independent addition of approximately 200 200 200 adenine residues by Poly-A Polymerase ; protects against 3 ′ 3' 3 ′ degradation and mediates nuclear export.

Splicing of Introns: Precise excision of non-coding introns by the spliceosome , a dynamic complex of five small nuclear ribonucleoproteins ( snRNPs: U1, U2, U4, U5, U6 ). Splicing occurs via two transesterification reactions: the branch-point adenosine ( 2 ′ -OH 2'\text{-OH} 2 ′ -OH ) attacks the 5 ′ 5' 5 ′ splice donor site ( 5 ′ -GU- 3 ′ 5'\text{-GU-}3' 5 ′ -GU- 3 ′ ), forming a looped lariat intermediate , followed by cleavage at the 3 ′ 3' 3 ′ splice acceptor site ( 3 ′ -AG- 3 ′ 3'\text{-AG-}3' 3 ′ -AG- 3 ′ ). Autoantibodies to snRNP core proteins ( anti-Smith / anti-Sm ) are highly specific for Systemic Lupus Erythematosus (SLE); anti-U1 RNP antibodies characterize Mixed Connective Tissue Disease (MCTD).

  • The Genetic Code, Translation, and Ribosomal Peptidyl Transfer
  • Characteristics of the Genetic Code

Unambiguous: Each codon (triplet of nucleotides) specifies exactly one amino acid.

Degenerate / Redundant: 61 sense codons specify only 20 amino acids (e.g., leucine is encoded by 6 different codons). The exceptions are Methionine (AUG) and Tryptophan (UGG) , encoded by single codons. Redundancy is accommodated by Crick's Wobble Hypothesis , which permits non-Watson-Crick base pairing between the 3 ′ 3' 3 ′ base of the mRNA codon and the 5 ′ 5' 5 ′ base of the tRNA anticodon.

Universal: Conserved across all known life (with minor exceptions in human mitochondrial DNA).

Non-overlapping and Comma-less: Read continuously, three nucleotides at a time, from a fixed start codon.

Translation Phases

Initiation: Small ribosomal subunit ( 40 S 40\text{S} 40 S ) binds the 5 ′ 5' 5 ′ cap and scans for the AUG start codon (coding for Methionine in eukaryotes; N-formylmethionine in prokaryotes). Assembly of the 60 S 60\text{S} 60 S subunit forms the active 80 S 80\text{S} 80 S ribosome, placing Met-tRNA in the P site (requires GTP).

Elongation: Incoming aminoacyl-tRNA binds the A site (facilitated by elongation factors and GTP). Peptidyl Transferase (a ribozyme within the 28 S 28\text{S} 28 S rRNA of the large subunit) forms a peptide bond between the P-site amino acid and the A-site amino acid. The ribosome translocates three nucleotides downstream, shifting the deacylated tRNA to the E site (exit) and the growing peptide chain to the P site.

Termination: When a stop codon ( UAA, UAG, UGA ; Mnemonic: " U A re A way, U A re G one, U G o A way") enters the A site, eukaryotic release factors (eRFs) bind, cleaving the completed polypeptide chain from the tRNA.

Regulation of gene expression and the molecular basis of oncogenesis

Genes are switched on and off by:

transcription factors at promoters and enhancers (for example steroid-hormone receptors);

chromatin modification : histone acetylation opens chromatin, while DNA methylation at CpG islands silences genes, the basis of imprinting and X-inactivation;

alternative splicing ;

microRNAs , which block translation or degrade mRNA.

In cancer, proto-oncogenes are activated by point mutation ( KRAS ), amplification ( HER2 ) or translocation ( BCR-ABL , MYC ). Tumor suppressors ( TP53 , RB , APC ) are lost by two hits. Epigenetic silencing, such as MLH1 promoter methylation, can also inactivate a gene.

Techniques in molecular biology

Technique Detects or does Clinical use

PCR Amplifies a target DNA sequence through cycles of denaturation, primer annealing and extension (Taq polymerase) Infectious disease detection, genotyping, paternity

RT-PCR and real-time (quantitative) PCR Reverse-transcribes RNA to cDNA, then amplifies it SARS-CoV-2 and HIV viral load; GeneXpert MTB/RIF (real-time PCR detecting M. tuberculosis and rifampicin resistance)

  • Southern blot DNA Gene rearrangements, trinucleotide repeat expansions
  • Northern blot RNA Gene expression
  • Western blot Protein (antibody detection) Confirmatory tests (historically HIV)
  • ELISA Antigen or antibody Screening (HIV, hepatitis B surface antigen, dengue NS1 and IgM)
  • FISH Specific DNA sequences on chromosomes Microdeletions (22q11), translocations, HER2 amplification
  • Karyotyping Chromosome number and large structural changes Down, Turner and Klinefelter syndromes
  • Microarray Copy-number changes and expression profiles Developmental delay work-up

DNA sequencing (Sanger, next-generation) Base-by-base sequence Mutation panels, whole-exome diagnosis, outbreak genomics

Restriction enzymes and RFLP Cut DNA at specific sites Older genetic testing, DNA fingerprinting

Molecular and gene-based therapy includes:

  • recombinant proteins (insulin, erythropoietin, clotting factors);
  • monoclonal antibodies (rituximab, trastuzumab);
  • targeted kinase inhibitors (imatinib);
  • antisense oligonucleotides;
  • gene therapy with viral vectors (for ADA-SCID, spinal muscular atrophy);
  • mRNA vaccines;

emerging CRISPR-Cas9 gene editing (approved for sickle cell disease).

Enzymes: properties, kinetics and regulation

Enzymes are biological catalysts, mostly proteins (ribozymes are RNA). They lower the activation energy but do not change the equilibrium or the free energy of the reaction. Many need cofactors (metal ions such as Zn2+, Mg2+ and Cu2+) or coenzymes , which are usually vitamin-derived (TPP, FAD, NAD+, PLP, biotin).

Michaelis-Menten kinetics: v = V m a x [ S ] K m + [ S ] v = \frac{V_{max}[S]}{K_m + [S]} v = K m ​ + [ S ] V ma x ​ [ S ] ​

Km is the substrate concentration at which velocity is half of Vmax. A low Km means high affinity : hexokinase has a low Km and glucokinase a high Km.

Vmax is proportional to the amount of enzyme.

On a Lineweaver-Burk (double-reciprocal) plot, the y-intercept is 1/Vmax, the x-intercept is -1/Km and the slope is Km/Vmax.

Inhibition type Binding Km Vmax Overcome by more substrate? Examples

Competitive Active site, resembles substrate Raised Unchanged Yes Methotrexate (dihydrofolate reductase), statins, ethanol versus methanol at alcohol dehydrogenase, malonate (succinate dehydrogenase)

  • Noncompetitive Separate site Unchanged Lowered No Many allosteric inhibitors, heavy metals
  • Uncompetitive Enzyme-substrate complex only Lowered Lowered No Lithium (inositol monophosphatase)

Irreversible Covalent Effectively lowers active enzyme Lowered No Aspirin (acetylates COX), organophosphates (acetylcholinesterase), proton pump inhibitors

Regulation of enzyme activity:

Allosteric control gives sigmoidal kinetics, for example ATP and citrate inhibiting PFK-1.

Covalent modification : phosphorylation by kinases, dephosphorylation by phosphatases (glycogen phosphorylase and synthase).

Zymogen activation by proteolysis: trypsinogen, clotting factors.

Induction or repression of enzyme synthesis: insulin induces glucokinase; heme represses ALA synthase.

Compartmentalization , as with the urea cycle split between mitochondria and cytosol.

Feedback inhibition by the end product.

Isoenzymes catalyze the same reaction but differ in structure and tissue distribution, for example LDH 1 to 5, CK-MM, CK-MB and CK-BB, and alkaline phosphatase from bone versus liver.

Clinical enzymology:

ALT (more liver-specific) and AST (also heart and muscle; AST more than twice ALT suggests alcoholic liver disease);

  • ALP and GGT (cholestasis);
  • amylase and lipase (pancreatitis; lipase more specific);
  • CK-MB (myocardium, now largely replaced by cardiac troponins , which are not enzymes);
  • acid phosphatase (prostate, semen);

G6PD (newborn screening).

Sphingolipidoses and Lysosomal Storage Disorders

Sphingolipidoses are autosomal recessive disorders (except X-linked Fabry disease) caused by deficiencies of specific lysosomal acid hydrolases, leading to progressive accumulation of undegraded sphingolipids within the reticuloendothelial system and central nervous system.

High-Yield Differential Diagnosis of Sphingolipidoses

Disease Deficient Enzyme Accumulated Substrate Clinical Features Diagnostic Pathognomonic Signs

Tay-Sachs Disease Hexosaminidase A GM 2 \text{GM}_2 GM 2 ​ Ganglioside Progressive neurodegeneration, hyperacusis (startle response), developmental regression, blindness Cherry-red spot on macula; onion-skin lysosomal lamellae; NO hepatosplenomegaly

Niemann-Pick Disease (Type A; type B spares the brain) Acid Sphingomyelinase Sphingomyelin Progressive neurodegeneration (type A), failure to thrive, early mortality Cherry-red spot on macula; marked hepatosplenomegaly ; lipid-laden "foam cells" in bone marrow

Gaucher Disease (Type 1) β \beta β -Glucocerebrosidase ( β \beta β -Glucosidase) Glucocerebroside Most common lysosomal storage disease; hepatosplenomegaly, pancytopenia, bone crises, osteonecrosis of femoral heads Gaucher cells with "crumpled tissue paper" appearance; "Erlenmeyer flask" deformity of distal femur

Fabry Disease α \alpha α -Galactosidase A (X-linked recessive) Ceramide Trihexoside (Globotriaosylceramide) Episodic burning pain in extremities (acroparesthesias), hypohidrosis, angiokeratomas Proteinuria, renal failure, early hypertrophic cardiomyopathy and stroke

Krabbe Disease Galactocerebrosidase Galactocerebroside and Psychosine Peripheral neuropathy, severe developmental delay, optic atrophy, spasticity Globoid cells (multinucleated macrophages) in white matter demyelination

Metachromatic Leukodystrophy Arylsulfatase A Cerebroside Sulfate (Sulfatides) Central and peripheral demyelination, ataxia, hypotonia progressing to spasticity, dementia Metachromatic granules with cresyl violet staining; peripheral nerve biopsy demyelination